Last reviewed · How we verify

Cipla BioTec Pvt. Ltd. — Portfolio Competitive Intelligence Brief

Cipla BioTec Pvt. Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
CBT124 CBT124 phase 3 small molecule unknown unknown
EU-sourced Avastin® EU-sourced Avastin® phase 3 VEGF inhibitor (monoclonal antibody) VEGF (Vascular Endothelial Growth Factor) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Pfizer · 2 shared drug classes
  2. University of Sao Paulo · 2 shared drug classes
  3. Avalo Therapeutics, Inc. · 1 shared drug class
  4. Bio-Thera Solutions · 1 shared drug class
  5. Centus Biotherapeutics Limited · 1 shared drug class
  6. Chang Gung Memorial Hospital · 1 shared drug class
  7. ChemRar Research and Development Institute, LLC · 1 shared drug class
  8. Barnes Retina Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Cipla BioTec Pvt. Ltd.:

Cite this brief

Drug Landscape (2026). Cipla BioTec Pvt. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cipla-biotec-pvt-ltd. Accessed 2026-06-10.

Related